Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue:
Royalty income	$ 2,119	$ 2,189
License revenue	215	242
Other revenue	13	19
Total revenue	2,347	2,450
Operating expenses:
Research and development	10,005	9,149
General and administrative	5,695	5,817
Change in contingent consideration liability	1,900	200
Total operating expenses	17,600	15,166
Operating loss	(15,253)	(12,716)
Other (expense) income:
Interest (expense) income, net	(1,107)	43
Total other (expense) income	(1,107)	43
Net loss	(16,360)	(12,673)
Net loss attributable to noncontrolling interests		(18)
Net loss attributable to Progenics	$ (16,360)	$ (12,655)
Net loss per share attributable to Progenics - basic and diluted (in dollars per share)	$ (0.23)	$ (0.18)
Weighted-average shares - basic and diluted (in shares)	70,196	69,946